MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 26 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Philipp Harter, Fabian Trillsch, Aikou Okamoto, Alexander Reuß, Jae‐Weon Kim, María Jesús Rubio-Pérez +14 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
54
citations
affaboutunlabeled
Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group
Raymond Ng, Baktiar Hasan, Nicole Mittmann, Marie Florescu, Frances A. Shepherd, Keyue Ding +9 more
2007· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
53
citations
affunlabeled
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Susana Banerjee, Sandro Pignata, Nicoletta Colombo +14 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
53
citations
affno abstractunlabeled
Not Just Tired
M. J. Poulson
2003· article· en· Journal of Clinical Oncology
machine prediction:candidate · noneconsensus · none
51
citations
affunlabeled
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Hedy L. Kindler, Nofisat Ismaila, Lyudmila Bazhenova, Quincy S. Chu, Jane E. Churpek, Ibiayi Dagogo‐Jack +14 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
51
citations

How this was built: Screen · Findings · About